How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/haemophilus-influenzae-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Haemophilus influenzae pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haemophilus influenzae pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Haemophilus influenzae pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xenleta	LEFAMULIN	Hong Kong	Pleuromutilin Antibacterial		2019-01-01
Zerbaxa	CEFTOLOZANE	Cubist Pharms	Cephalosporin Antibacterial		2014-01-01
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	Cephalosporin Antibacterial		2010-01-01
Tygacil	Tigecycline	Pfizer	Tetracycline	Bacterial protein synthesis	2005-01-01
Ketek	TELITHROMYCIN	Sanofi	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 18 drugs in Haemophilus influenzae pneumonia
Bristol-Myers Squibb · 4 drugs in Haemophilus influenzae pneumonia
Merck & Co. · 2 drugs in Haemophilus influenzae pneumonia
Merck Sharp & Dohme B.V. · 2 drugs in Haemophilus influenzae pneumonia
Pfizer · 2 drugs in Haemophilus influenzae pneumonia
Lg Chem Ltd · 2 drugs in Haemophilus influenzae pneumonia
Pai Holdings Pharm · 2 drugs in Haemophilus influenzae pneumonia
GSK · 2 drugs in Haemophilus influenzae pneumonia
Bayer AG · 2 drugs in Haemophilus influenzae pneumonia
Fresenius Kabi · 1 drug in Haemophilus influenzae pneumonia
Bayer Pharmaceuticals Corp · 1 drug in Haemophilus influenzae pneumonia
Allergan · 1 drug in Haemophilus influenzae pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Haemophilus influenzae pneumonia:

Cite this brief

Drug Landscape (2026). Haemophilus influenzae pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/haemophilus-influenzae-pneumonia. Accessed 2026-06-11.

Haemophilus influenzae pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing